

17236 U.S. PTO
022504

Express Mail No.: ET731051267US
Docket No.: EYE-010CON

22858 U.S. PTO
10/786491
022504

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
CONTINUING APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

**MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Sir:

Transmitted herewith for filing is the patent application of:

Inventor(s): **David R. Guyer**

Title: **Methods for Treating Ocular Neovascular Diseases**

1. Type of application


- This is a request under 37 CFR 1.53 for filing a
 - Continuation application. □ Divisional application

This application is a continuation of U.S. Application Serial No. 10/291,091,
filed November 8, 2002, which claims priority to U.S. Provisional Application
Serial No. 60/332,304, filed on November 9, 2001.

- Applicants claim small entity status (See 37 CFR 1.27)

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Patent Application Transmittal and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on February 25, 2004 in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. ET731051267US


Anna Dushine

2. Application Papers Enclosed

- 1 Title Page
- 42 Pages of Specification (excluding Claims, Abstract, Drawings & Sequence Listing)
- 3 Page(s) of Claims
- 1 Page(s) of Abstract
- 1 Sheet(s) of Drawings ☒ Formal ☐ Informal

3. Oath or Declaration

- ☒ An executed declaration of the inventor(s) is enclosed
- ☐ Unexecuted – the undersigned attorney or agent is authorized to file this application on behalf of the applicant(s). An executed declaration will follow.

4. Additional Papers Enclosed

- ☐ Preliminary Amendment
- ☐ Information Disclosure Statement
- ☐ Assignment Document
- ☐ A bibliographic data entry sheet
- ☐ Verified translation of a non-English patent application
- ☐ Nonpublication Request Under 35 USC 122(b)(2)(B)(i)
- ☒ Return receipt postcard
- ☐ Other _____

5. Priority Applications Under 35 USC 119

Certified copies of applications from which priority under 35 USC 119 is claimed are listed below and

- ☐ are attached ☐ will follow.

6. **Filing Fee Calculation (37 CFR 1.16)**

UTILITY APPLICATION

CLAIMS AS FILED – INCLUDING PRELIMINARY AMENDMENT (IF ANY)						
			SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
BASIC FEE				\$385.00		\$770.00
TOTAL	20-20	= 0	X 9 =	\$0.00	X 18 =	\$0.00
INDEP.	2-3	= 0	X 43 =	\$0.00	X 86 =	\$0.00
First Presentation of Multiple Dependent Claim			+ 145 =	\$0.00	+ 290 =	\$0.00
FILING FEE:				\$385.00	OR	\$0.00

OTHER FEES

☐ Recording Assignment [Fee -- **\$40.00** per assignment] \$ _____

TOTAL FEES \$ **385.00**

7. Method of Payments of Fees


- ☐ Enclosed check
- ☒ Charge Deposit Account No. 503008. A duplicate copy of this transmittal is enclosed
- ☐ Fees are not enclosed

Please direct all future correspondence to **CUSTOMER NO. 40336**.

Respectfully submitted,

Date: February 25, 2004

By:



Michael J. Rafa
Attorney for Applicants
Reg. No. 38740
Customer No. 40336
Eyeteck Pharmaceuticals, Inc.
500 Seventh Avenue, 18th Floor
New York, NY 10018
Tel.: (212) 997-9241
Fax: (212) 997-9251